Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
CAR T with fully human single-domain antibody fragment targeting GPRC5D shows ORR 94.4% (72.2% CR/sCR) and 85.7% if prior BCMA CAR T-cell therapy; median PFS 18.2 months; CRS in 88.9% (primarily grade 1-2); 1 grade 3 ICANS.”
Title: Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma
Authors: Mengmeng Pan, Di Wang, Jie Xu, Shiwei Jin, Yan Wang, Yi Tao, Yuanfang Liu, Wanyan Ouyang, Xiangqin Weng, Hongmei Yi, Yu Huang, Xinmei Cao, Shuhua Li, Fuyuan Zhang, Weiping Zhang, Chunrui Li, Jian-Qing Mi
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
